Anti-hIL-29 Neutralizing mAb

Neutralizing monoclonal antibody against human interleukin 29

Neutralizing monoclonal antibody against human IL-29

Anti-hIL-29-IgG (clone 6A11) is a monoclonal antibody (mAb) for human interleukin 29 (hIL-29). It is produced in hybridomas and purified by affinity chromatography. This antibody has been selected for its ability to efficiently neutralize the biological activity of hIL-29. IL-29 (also known as interferon lambda 1) is a member of the type III interferon (IFN lambda) cytokine family that exhibits several common features with type I IFNs: antiviral activity and antitumor activity [1, 2]. 

More details

Key features:

• A potent neutralizing mAb against hIL-29
• Provided azide-free
• Each lot is functionally tested

References:

1. Donnelly RP. & Kotenko SV., 2010. Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res. 30(8):555-64.
2. Li M. et al., 2009. Interferon-ls: the modulators of antivirus, antitumor, and immune responses. J. Leukoc. Biol., 86:23-32.

Figures

Dose-dependent inhibition of HEK-Blue™ IFN-λ cell response using anti-hIL29-IgG mAb. A serial dilution of Anti-hIL-29-IgG monoclonal antibody (mAb) was incubated with 0.25 ng/ml of recombinant hIL-29 for 30 minutes prior to the addition of the HEK-Blue™ IFN-λ cells. After 24 hours, the SEAP activation was determined. Data is shown as the percentage of neutralization (mean ± SEM).

Specifications

Target: Natural and recombinant human interleukin-29 (IL-29)

Specificity: Reacts with human IL-29, human IL-28A, and human IL-28B.
No cross-reactivity with mouse IL-28A or mouse IL-28B.
Note: An active IL-29 gene is absent in mice.

Clone: 6A11

Isotype: Mouse IgG2a, kappa

Control: Mouse IgG2a Control

Immunogen: Human IL-29 protein expressed in Swiss mice following DNA immunization

Formulation: 0.2 µm filtered solution in sodium phosphate buffer with glycine, saccharose, and stabilizing agents

Tested applications: Blocking & Neutralisation

Contents

• 3 x 100 μg purified anti-hIL-29-IgG antibody, provided azide-free and lyophilized

Product is shipped at room temperature.

Store lyophilized antibody at -20 °C.

Details

Interleukin-29 (IL-29) is a member of the type III interferon (IFN lambda) cytokine family, which comprises four distinct proteins called IFN-λ1 (interleukin-29, IL-29), IFN-λ2 (IL-28A), IFN-λ3 (IL-28B), and the poorly secreted IFN-λ4. It should be noted that in the mouse genome IL-29 is a pseudogene. Type III IFNs exhibit several common features with type I IFNs: antiviral activity and antitumor activity [1, 2]. In fact, it has been demonstrated that IL-29 works together with type I IFN to promote an antiviral response to hepatitis [3]. IL-29 is produced by monocytes and dendritic cells in response to viral infection and stimulation with toll-like receptor (TLR) ligands [4]. IL-29 exerts its action following binding to a heterodimeric protein complex composed of two subunits, IFN lambda receptor 1 (IFNLR1) and IL-10 receptor beta (IL10Rβ). This leads to the recruitment of the Janus kinases, JAK1 and TyK2, and phosphorylation of STAT1 and STAT2, which then dimerize and interact with IFN regulatory factor 9 (IRF9), forming the ISGF3 complex. ISGF3 binds to IFN-stimulated response elements (ISRE) in the promoters of IFN-stimulated genes (ISG) to regulate their expression.

1. Donnelly RP. & Kotenko SV., 2010. Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res. 30(8):555-64.
2. Li M. et al., 2009. Interferon-ls: the modulators of antivirus, antitumor, and immune responses. J. Leukoc. Biol., 86:23-32.
3. Pagliaccetti NE. et al., 2008. Interleukin-29 functions cooperatively with interferon to induce antiviral gene expression and inhibit hepatitis C virus replication. J Biol Chem. 283(44):30079-89.
4. Wolk K. et al., 2008. Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes. J. Leukoc Biol. 83(5):1181-93.